Safety observation study for healthy individuals of intravenous administration of NMN.

Safety observation study for healthy individuals of intravenous administration of NMN. - Safety assessment of NMN infusion therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047134

Enrollment

Registered

2022-03-09

Start date

2021-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy individuals

Interventions

Single intravenous administration of NMN.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The healthy subjects who agree to the study.

Exclusion criteria

Exclusion criteria: 1. The subjects with a previous history of diseases. 2. The subjects with malignant neoplasms. 3. The subjects with serious infections. 4. The subjects with psychiatric disorders. 5. The subjects with ophthalmic disorder. 6. The subjects with allergic disorders. 7. The subjects who are regarded as inadequate by the investigator.

Design outcomes

Primary

Measure	Time frame
Safety of intravenous administration of NMN (clinical parameters).	—

Secondary

Measure	Time frame
Analysis of NAD+ levels and SIRT1 activation in blood.	—

Countries

Japan

Contacts

Public ContactShintarou Kimura

StateArt Inc. Research and Development Department

s.kimura@stateart.co.jp03-5859-5193

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026